![]() We now supply over 67% of all medicines in Europe, and over the last ten years, generic medicines have increased access to medicines by over 100% in 7 key therapeutic areas. ![]() Better access to the most effective therapies means millions more patients are getting better and living longer, while healthcare inequalities are being reduced. Our members provide the essential medicines that European patients, healthcare professionals and healthcare systems rely on to treat the most acute and chronic diseases ailments covering a wide range of diseases from cardiovascular, to diabetes and cancer. As more of these medicines came off-patent, and the benefits and value of generics to both patients and healthcare providers became clearer, so the provision of generic medicines has increased dramatically. When the EGA was first launched back in 1993, generic alternatives to branded medicines made up a fraction of the market. ![]() As the pharmaceutical industry and the healthcare environment within which it operates have evolved, so has our Association. Medicines for Europe began over 20 years ago as the European Generics Medicines Association (EGA) with the goal of representing the emerging generic industry, and later growing to include biosimilar medicines to its portfolio. About Medicines for Europe PURPOSE AND OBJECTIVES OUR VALUES – OUR 5 PILLARS STRUCTURE MEMBERS BECOME A MEMBER CODE OF CONDUCT DISCLOSURE
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |